ArriVent BioPharma GAAP EPS of -$4.32 beats by $0.05
Source: SeekingAlpha
2026-03-05 16:31:35 ET
More on ArriVent BioPharma
- ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy
- ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts
- Seeking Alpha’s Quant Rating on ArriVent BioPharma
- Historical earnings data for ArriVent BioPharma
- Financial information for ArriVent BioPharma
Read the full article on Seeking Alpha
For further details see:
ArriVent BioPharma GAAP EPS of -$4.32 beats by $0.05
ArriVent BioPharma Inc.
NASDAQ: AVBP
AVBP Trading
-5.73% G/L:
$25.075 Last:
292,138 Volume:
$25.33 Open:
AVBP Latest News
AVBP Stock Data
$870,211,090
25,421,062
2.66%
32
N/A
Biotechnology & Life Sciences
Healthcare
US
Newtown Square
